

Qiagen expands portfolio for minimal residual disease testing in oncology

03 June 2025 | News

Two new partnerships enhance Qiagen's capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities



Netherlands-based holding company Qiagen N.V. has announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (MRD) testing in clinical trials to support pharma codevelopment projects for companion diagnostics.

The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand Qiagen's reach in MRD testing and cover solid tumours and hematological cancers.

Minimal residual disease (MRD) testing is becoming a cornerstone of oncology by enabling early detection of cancer recurrence and guiding timely adjustments to therapy from a blood sample. These new partnerships support the growing demand for decentralised, non-invasive tools that advance precision medicine and help deliver more personalised care.

Tracer Biotechnologies, a developer of blood-based molecular diagnostics for cancer, is working with Qiagen to create companion diagnostics for MRD testing in solid tumours. These assays, designed for use on Qiagen's QIAcuity digital PCR platform, are designed to enable the use of minimally invasive blood samples to monitor residual disease with high sensitivity.

Foresight Diagnostics and Qiagen are creating a kit-based version of the Foresight CLARITY™ assay, a circulating tumour DNA (ctDNA)-based NGS test for certain types of lymphoma.